Coronavirus LIVE Updates | India Reports 17,407 New Cases, Arvind Kejriwal Takes First Dose Of Covishield

The COVID-19 cases are on a rise once again, India witnessed a spike of 17,407 new infections in the last 24 hours.

14,031 discharges and 89 deaths were recorded during this period. The country’s coronavirus tally has reached 1,11,39,516 including 1,08,26,075 recoveries and 1,57,435 deaths.

With 83,556 active coronavirus infections, Maharashtra has the highest number of cases in the country. Kerala follows with 46,288 active cases.

According to the Health Ministry, more than one crore sixty lakh people have been vaccinated across the county. The latest to join the list is Delhi CM Arvind Kejriwal. He along with his parents got the first dose of the vaccine at the LNJP hospital.

Jammu and Kashmir Lieutenant Governor Manoj Sinha also administered the first dose of a COVID-19 vaccine at the Government Medical College and Hospital, Jammu.

A total of 1,63,14,485 vaccine doses have been given, as per the provisional report till 7 pm on Wednesday. These include 67,75,619 healthcare workers who have taken the first dose and 28,24,311 HCWs who have taken the second dose, 57,62,131 frontline workers (1st dose), 3,277 FLWs (2nd dose), 8,44,884 beneficiaries more than 60 years old, and 1,04,263 beneficiaries aged 45 and above with specific co-morbidities.

Bharat Biotech on Wednesday released results of Phase 3 clinical trials of its coronavirus vaccine Covaxin, with the drug demonstrating 81 percent interim efficacy against Covid-19.

“The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81 percent in its phase III clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research (ICMR), the biotech company said in a release. The company said the phase III study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with co-morbidities.

“The primary endpoint of phase III clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) Covid-19 with onset at least 14 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline,” it stated.

India on Monday commenced the next phase of the world’s largest Covid-19 vaccination drive for people over 60 years of age and those above 45 with co-morbidities.

The global COVID-19 cases have climbed to 113 million, while the death toll due to the virus crossed 2.5 million, according to Johns Hopkins University.

LIVE UPDATES 

Click here for Latest News updates and viral videos on our AI-powered smart news

For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us on Instagram

 

 

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here